CN115135324A - 通过靶向冷肿瘤治疗癌症的方法 - Google Patents

通过靶向冷肿瘤治疗癌症的方法 Download PDF

Info

Publication number
CN115135324A
CN115135324A CN202080056280.1A CN202080056280A CN115135324A CN 115135324 A CN115135324 A CN 115135324A CN 202080056280 A CN202080056280 A CN 202080056280A CN 115135324 A CN115135324 A CN 115135324A
Authority
CN
China
Prior art keywords
tumor
cancer
patient
therapy
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080056280.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·福克斯
I·阿隆希克
T·周
E·费瓦洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN115135324A publication Critical patent/CN115135324A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080056280.1A 2019-06-13 2020-06-12 通过靶向冷肿瘤治疗癌症的方法 Pending CN115135324A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861094P 2019-06-13 2019-06-13
US62/861,094 2019-06-13
PCT/US2020/037521 WO2020252331A1 (en) 2019-06-13 2020-06-12 Methods of treating cancer by targeting cold tumors

Publications (1)

Publication Number Publication Date
CN115135324A true CN115135324A (zh) 2022-09-30

Family

ID=73781074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080056280.1A Pending CN115135324A (zh) 2019-06-13 2020-06-12 通过靶向冷肿瘤治疗癌症的方法

Country Status (10)

Country Link
US (1) US12357633B2 (https=)
EP (1) EP3983016A4 (https=)
JP (1) JP2022536412A (https=)
KR (1) KR20220024426A (https=)
CN (1) CN115135324A (https=)
AU (1) AU2020290508A1 (https=)
CA (1) CA3143030A1 (https=)
IL (1) IL288939A (https=)
MX (1) MX2021015447A (https=)
WO (1) WO2020252331A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117538544A (zh) * 2023-11-22 2024-02-09 湛江中心人民医院 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4114398A1 (en) * 2020-03-06 2023-01-11 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
CN113421613B (zh) * 2021-06-08 2024-06-18 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
AU2024337882A1 (en) * 2023-09-07 2026-02-19 Sutter Bay Hospitals Co-targeting ncoa3 and pd-1 for cancer therapy
KR20250143182A (ko) * 2024-03-21 2025-10-01 차의과학대학교 산학협력단 시스플라틴에 대한 반응성의 예후를 나타내는 비소세포폐암 환자의 분류를 위한 분석방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031658A1 (en) * 2016-08-10 2018-02-15 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160116474A1 (en) * 2013-06-20 2016-04-28 The Broad Institute, Inc. Compositions and methods for detecting and treating glioblastoma
KR102400920B1 (ko) 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
LT3371152T (lt) * 2015-11-05 2021-04-12 Celgene Quanticel Research, Inc. Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui
US11998540B2 (en) * 2015-12-11 2024-06-04 The General Hospital Corporation Compositions and methods for treating drug-tolerant glioblastoma
MA51507A (fr) * 2016-12-09 2020-11-11 Constellation Pharmaceuticals Inc Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031658A1 (en) * 2016-08-10 2018-02-15 Celgene Corporation Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
CN109803660A (zh) * 2016-08-10 2019-05-24 细胞基因公司 复发性和/或难治性实体瘤和非霍奇金淋巴瘤的治疗
WO2019083971A1 (en) * 2017-10-23 2019-05-02 Children's Medical Center Corporation METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117538544A (zh) * 2023-11-22 2024-02-09 湛江中心人民医院 检测基因Ccdc181表达量的试剂在制备精子异常诊断产品中的应用

Also Published As

Publication number Publication date
MX2021015447A (es) 2022-04-06
AU2020290508A1 (en) 2022-01-27
IL288939A (en) 2022-02-01
KR20220024426A (ko) 2022-03-03
US12357633B2 (en) 2025-07-15
CA3143030A1 (en) 2020-12-17
WO2020252331A1 (en) 2020-12-17
EP3983016A1 (en) 2022-04-20
US20220273654A1 (en) 2022-09-01
JP2022536412A (ja) 2022-08-16
EP3983016A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CN115135324A (zh) 通过靶向冷肿瘤治疗癌症的方法
US10973829B2 (en) Therapeutic uses of a C-RAF inhibitor
De Groot et al. CDK4/6 inhibition in early and metastatic breast cancer: A review
JP6911019B2 (ja) Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬
EP3662903A2 (en) Combination therapies
CN111032082B (zh) Her2阳性癌症的治疗
CN117205313A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
JP2019518426A (ja) がんの診断及び治療方法
WO2016015095A1 (en) A method for the identification of immunotherapy-drug combinations using a network approach
WO2023114984A1 (en) Tead inhibitors and uses thereof
CN113396230A (zh) 癌症的诊断和治疗方法
Kjær et al. Cetuximab resistance in squamous carcinomas of the upper aerodigestive tract is driven by receptor tyrosine kinase plasticity: potential for mAb mixtures
JP2026053570A (ja) Ｋｒａｓ ｇ１２ｃ変異を含む癌を治療するためのソトラシブ及びｅｇｆｒ抗体
Del Prete et al. Noncutaneous melanomas: a single-center analysis
US11351163B2 (en) Compositions and methods of treating cancer
JP2022502491A (ja) 骨髄増殖性疾患の治療法
US20200385478A1 (en) Compositions and methods for cancer immunotherapy
Madhukar et al. Current and Potential Pharmacological Targets for Therapeutic Intervention in Head and Neck Squamous Cell Carcinoma
WO2021202961A1 (en) Methods of treating immunotherapy resistant metastatic melanoma
Takaidza et al. Molecular Basis of Cancer: Genetic Alterations and Tumor Development
TW202604567A (zh) 天門冬醯胺抑制劑與免疫檢查點抑制劑的組合用於治療癌症的用途及包含天門冬醯胺抑制劑與免疫檢查點抑制劑的組合之醫藥組成物
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c
HK40055955A (en) Diagnostic and therapeutic methods for cancer
HK40032701A (en) Diagnostic and therapeutic methods for cancer
David et al. Noncutaneous Melanomas: A Single-Center Analysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220930